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lacking a molecular diagnosis. A refined locus for adRP on Chr17q22 (RP17) was delineated through genotyping and genome
sequencing, leading to the identification of structural variants (SVs) that segregate with disease. Eight different complex SVs were char-
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(RP [MIM: 268000]), which is genetically heterogeneous,
with a prevalence of 1 in 4,000.3 RP is defined as a
retinal degeneration that primarily affects rod photore-
ceptors, resulting in night blindness and progressive
loss of peripheral vision, often progressing into the
central retina and affecting cone photoreceptors,
leading to severe visual impairment or blindness (see
‘‘Nonsyndromic Retinitis Pigmentosa Overview’’ in Web
Resources). Autosomal-dominant RP (adRP) accounts
for 25%–40% of cases, depending on the population
studied, and has been associated with mutations
in 30 genes, including CA4 (MIM: 114760) on
Chr17q23.1 (RP17 [MIM: 600852])(see ‘‘RetNet’’ in Web
Resources).4,5 Following initial publications defining
this locus6,7 a variant in CA4 was implicated as the cause
of adRP in families of South African origin, however
pathogenicity of the reported variant has been ques-
tioned because it has a population frequency of 4% in
healthy controls in northern Sweden.8–10 Subsequently
reported CA4 variants in individuals with RP were iden-
tified by targeted Sanger sequencing and do not fully
exclude variants in other genes as a cause of disease
(Table S1).
We investigated the cause of adRP in unsolved families,
including the first pedigree (GC1, referred to as UK1)
drawn up at Moorfields Eye Hospital over 35 years ago
and the original Dutch family (W97-079, referred to as
NL1) that showed linkage to the RP17 locus but lacked a
mutation in CA4.7
Here, we report identification and characterization of
complex SVs on Chr17q22, through whole-genome
sequencing (WGS), as the genomic cause of adRP at
the RP17 locus in a large number of families, including
the families of South African origin. To explore a
convergent mechanism of disease, we investigated
the effect of RP17 SVs on three-dimensional (3D)
chromatin organization that results in the compart-
mentalization of the genome into topologically associ-
ating domains (TADs) and the epigenetic landscape of
the region. TADs are chromatin domains within the
genome that facilitate enhancer promoter contacts
within the nuclear 3D space.11 Disruption of TAD
structures can lead to loss of chromosomal contact
between regulatory regions and their target genes or
the formation of novel active domains with ectopic
contacts occurring between regulatory regions and a
new target gene, resulting in pathogenic alterations
in gene expression.12–15 We demonstrate that altered
TAD structure at the RP17 locus leads to ectopic
retinal enhancer-gene interactions, consistent with a
dominant gain of function. Our study highlights the
pathogenicity of SVs that alter 3D chromatin organiza-
tion and gene expression by rearranging TAD structures
and the need to revisit rare Mendelian diseases for which
genes and variants have not been substantiated in other
cohorts.2 The American Journal of Human Genetics 107, 1–13, November 5,Material and Methods
Study Cohort
The study was approved by the medical ethics committee of the
ErasmusMC Rotterdam, Radboudumc Nijmegen, and Moorfields
Eye Hospital and was performed in accordance with the principles
of the World Medical Association Declaration of Helsinki.
Informed consent was obtained from all participants or their legal
representatives.
Genetic Analyses
We performed SNP genotyping for index families NL1 and UK1
to define and refine the RP17 locus. Genomic DNA from affected
individuals and their family members was analyzed by whole-
exome sequencing (WES) and WGS. Sequence data was aligned
to the Human Reference Genome build hg19. Variants were
prioritized on the basis of a minor allele frequency (MAF) %
0.0001 in gnomAD. SVs were called with ExomeDepth, Manta
Structural Variant Caller, Canvas Copy Number Variant Caller,
and Control-FREEC. Details of genotyping, sequencing, and
analysis pipelines are provided in the Supplemental Material
and Methods.
Characterization and Validation of Structural Variants
SV breakpoint junctions were PCR amplified and validated with
Sanger sequencing. Primer sequences and coordinates are listed
in Table S2. SV breakpoint regions were assessed for the presence
of microhomology and repetitive elements. To validate a tripli-
cated region for UK-SV6, we performed quantitative real-time
PCR (qPCR) on genomic DNA from affected individuals from fam-
ily UK13 and unaffected controls (Supplemental Material and
Methods).
Clinical Analysis
Available clinical notes of cases for the pedigrees identified at Rad-
boudumc, Moorfields Eye Hospital, University of Cape Town, and
McGill University Health Centre were reviewed, as well as detailed
retinal imaging, fundus autofluorescence, and optical coherence
tomography. Age of onset is defined as the age at which symptoms
were first experienced.
Interrogation of the Genomic Region
We interrogated chromatin and genome regulation datasets to
explore the epigenomic landscape of the region. Available datasets
were obtained and analyzed via the UCSC genome browser (details
of datasets used are provided in Supplemental Material and
Methods).
Reprogramming Fibroblasts into iPSCs and
Differentiation into Photoreceptor Progenitor Cells and
3D Retinal Organoids
Fibroblasts were cultured from skin biopsies of two individuals
with NL-SV1, one individual with UK-SV2, and five anonymous
control individuals. Cell lines were reprogrammed into induced
pluripotent stem cells (iPSCs) and differentiated into photore-
ceptor progenitor cells (PPCs) following the previously described
60 day protocol (Supplemental Material and Methods).16,17 3D
retinal organoids (ROs) were differentiated for UK-SV2 and
controls, as previously described (Supplemental Material and
Methods).182020
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Hi-C was performed on UK-SV2 and control 3D ROs via a low
input protocol (Low-C) with few modifications (Supplemental
Material andMethods).19 Two libraries per sample were sequenced
for 200 million fragments in a 100 bp paired-end run on a Nova-
Seq 6000 (Illumina). Paired-end sequencing data was processed
via Juicer20 and the Hi-C maps were created with a bin size with
10 kb resolution. Further information about the bioinformatics
pipeline is detailed in Melo et al., 2020.21Expression Analysis of Genes and Enhancer RNA within
the RP17 Locus
To assess expression of genes, we performed qPCR for different hu-
man tissues, including retina (Table S3 and Supplemental Material
and Methods). Single-cell RNA sequencing data of human22 and
primate23 retinal cell types were obtained and visualized via the
Broad Institute Single Cell Portal (Supplemental Material and
Methods).
cDNA was synthesized from total RNA extracted from PPCs,
ROs, and fibroblasts. Differential expression of genes implicated
in the SVs, and control housekeeping and retinal progenitor
genes, was assessed by qPCR (Table S3 and Supplemental Material
and Methods). We designed primers to the enhancer region con-
taining multiple retinal transcription factor binding sites impli-
cated in all SVs to analyze targeted enhancer RNA expression by
qPCR (Table S3 and Supplemental Material and Methods).Results
Refinement of the RP17 Locus in Two Unrelated adRP-
Affected Families
The affected haplotype for a Dutch adRP-affected family
(NL1) (Figure 1A) was previously mapped to a 7.18 Mb
region spanning the RP17 locus on chromosome 17.7
The RP17 locus was refined to a 5.16 Mb interval by SNP
haplotyping in an extended pedigree (Figure 1D and
Supplemental Information). No rare coding or splice site
heterozygous variants (MAF % 0.0001) shared between
affected individuals were found through WES. Subse-
quently, WGS was performed, and similarly, no rare
candidate coding, splice site, intronic, or intergenic hetero-
zygous single-nucleotide variants were identified (Table S4
and Supplemental Information).
In parallel, WES and WGS were performed for affected
individuals from a genetically unexplained UK adRP-
affected family (UK1) (Figure 1B). This also failed to iden-
tify a rare causative variant; however, a disease-associated
haplotype on chromosome 17 was identified (Figure 1E,
Table S5, and Supplemental Information). Interrogation
of unsolved IRD sequence data generated through the UK
IRDC, UCL-Ex, NIHR-Bioresource, and Genomics England
identified other adRP probands that shared the same
haplotype of Chr17 SNVs and established this as a founder
haplotype in eleven additional UK adRP-affected families
(Figure 1C). The adRP locus was refined to a 4.4Mb interval
on Chr17q22 (Figure 1E). This genomic interval overlaps
the previously described RP17 locus in families of Dutch
and South African origin (Figure 1F).The AmA missense variant in CA4 [c.40C>T (p.Arg14Trp);
GenBank: NM_000717.4] was previously described as
the cause of adRP at the RP17 locus in families of South
African origin.8 No rare coding, intronic, or upstream
variants in CA4 were identified in the Dutch and UK
families.
Identification of Structural Variants within the RP17
Locus
Next, we analyzed genome and exome data for copy num-
ber variants and SVs (Supplemental Information). In family
NL1, WGS revealed a 226 kb duplication within the RP17
locus: chr17: 57,291,905_57,518,137dup (NL-SV1). This
SV involves two duplicated genes (GDPD1 [MIM: 616317]
and YPEL2 [MIM: 609723]), an intragenic microRNA
(MIR4729), and partial duplication of SMG8 (MIM:
613175) and the long non-coding RNA LINC01476.
The duplication creates a breakpoint junction (chr17:
g.57,518,137–57,291,905) specific for the mutated allele in
NL1 (Figures 2A, 2B, and S1), which was used to confirm
segregation of the SV with the adRP phenotype in this fam-
ily. No overlapping SVs in the RP17 locus were observed
in WES of ~7,500 individuals without retinal disease gener-
ated in-house at the Department of Human Genetics,
Radboudumc.
For the twelve UK RP17 founder haplotype fam-
ilies, WGS revealed a duplicated inversion: chr17:
57,456,098–57,468,960delins57,275,839_57,559,114inv
(UK-SV2) (Figure 2B). The SV was characterized, and
breakpoint junctions were validated (Figure S1 and Sup-
plemental Information). This SV involved four coding
genes (PRR11 [MIM: 615920], SMG8, GDPD1, and
YPEL2) and two non-coding RNA genes (MIR4729 and
LINC01476) (Figure 2B). UK-SV2 segregated with adRP
in all families for which DNA was available for analysis.
UK-SV2 was absent in WGS control genome data gener-
ated for 58,000 UK individuals (Genomics England).
Different Structural Variants within the RP17 Locus in
Multiple adRP-Affected Families
These data prompted us to investigate whether SVs were
present in the two original South African families (SA1
and SA2) that were linked to the RP17 locus
(Figure S2A).6,8 In addition, a Canadian adRP-affected fam-
ily (CA1) was also mapped to the RP17 locus (unpublished
data, Figure S2B). WGS was performed for affected individ-
uals from these families, and inversion duplication events
were identified in all samples analyzed (Figure 2C). In SA1
and SA2, an identical SV, SA-SV3, was revealed, suggesting
this is a founder variant in this population. SA-SV3 was
also found by breakpoint PCR in two additional families
of South African origin (SA3 and SA4), confirming the
founder effect (Figure S2A). In the Canadian family, a
different inversion duplication event was identified, CA-
SV4. SA-SV3 and CA-SV4 breakpoints were characterized
and validated (Figure S1), and segregation of the SVs with
the adRP phenotype was confirmed.erican Journal of Human Genetics 107, 1–13, November 5, 2020 3
Figure 1. Mapping of the RP17 Locus in Two Unrelated Families
(A) Pedigree of Dutch NL1 family.
(B) Pedigree of UK1 family.
(C) Pedigrees of additional UK families with the founder haplotype onChr17q.WGS orWESwas performed in individuals highlighted in
blue or red, respectively.
(D) SNP haplotyping results for NL1. The refined RP17 locus (rs8078110–rs9910672) is shared by all affected individuals (n¼ 35) and not
present in unaffected individuals (n¼ 28, only individuals with recombination close to or refining the critical region are depicted) with a
maximum LOD score of 15.0. The horizontal numbers represent the number of individuals with this haplotype.
(E) UK founder haplotype refining the RP17 locus in UK families. Representative haplotypes from several unrelated families are shown
with affected (aff) individuals compared to an unaffected (unaff) individual. Black lines and arrows indicate recombination events.
Shared haplotype in individuals is shaded red.
(F) Overlap of refined RP17 loci in UK, NL, and previously described SA families.8
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important cause of adRP. Therefore, WGS and WES data
for genetically unexplained adRP-affected families were4 The American Journal of Human Genetics 107, 1–13, November 5,analyzed for SVs within this locus. In four unrelated fam-
ilies of Dutch or UK origin, four additional unique com-
plex SVs were discovered (Figures 2D and S2C). For2020
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Figure 2. Overview of Structural Variants within the RP17 Locus in adRP-Affected Families
Breakpoints are indicated with dashed lines. Blue segments represent duplicated or triplicated regions, whereas inversions are high-
lighted in purple.
(A) Wild-type (WT) chromosomal organization.
(B) Structural variants identified in NL1 (NL-SV1) and UK founder haplotype families (UK-SV2).
(C) Structural variants identified in adRP-affected families that were previously linked to the RP17 locus; SA-SV38 and CA-SV4 (unpub-
lished data).
(legend continued on next page)
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WGS to determine the breakpoint junctions and identify
potential inversions or other SVs. In all families, break-
points were validated, and segregation analysis was per-
formed where possible. Triplication for UK-SV6 was
confirmed by qPCR in family UK13 (Figure S3 and Supple-
mental Information).
Details of all SVs identified in this study are shown in
Table S6, Figure 2, and Figure S4, and an overview of SV-
specific breakpoint junctions is shown in Figure S1. All
RP17 SVs share a common duplicated (or triplicated) re-
gion of 11.5 kb and harbor unique breakpoints disrupting
the genomic region spanning YPEL2 to LINC01476 (chr17:
57,499,214–57,510,765) (Figure S4).We analyzed all break-
point junction sequences to investigate the potential
mechanism(s) that created RP17 SVs. No single mecha-
nism could account for the RP17 SVs because a combina-
tion of (micro)homology-mediated repair and non-homol-
ogous end joining events were identified (Table S7 and S8,
Figure S5, and Supplemental Information).
Consistent Autosomal-Dominant Retinitis Pigmentosa
Phenotype for RP17-Affected Families
The SVs identified were fully penetrant in all families.
Available clinical data are presented in Table S9. Twenty-
four affected individuals from seventeen pedigrees were
evaluated. There is significant correlation of phenotype
across all genotypes with relatively mild disease, decreased
visual acuity, visual field constriction, nyctalopia, and slow
progression consistent with adRP. Many affected individ-
uals have preserved central visual function and acuity until
the 6th–7th decade. Foveal sparing and cystoid macular
edema were a common finding in individuals with UK-
SV2. On the basis of a small number of affected individuals
(n ¼ 2), UK-SV6 (with a triplicated SV) may be associated
with an earlier age of onset and more severe phenotype
(Figure S6).
Topologically Associating Domain Structure and
Epigenetic Landscape of the RP17 Genomic Region
All of the RP17 SVs lead to disruption of the genomic re-
gion spanning YPEL2 to LINC01476 (Figure 2E). SVs
that interfere with genome structure can have distinct ef-
fects on gene regulation depending on the type and
extent of the SV and landscape of the genomic region.15
TADs are separated by boundaries, regions of low chro-
matin interaction that insulate the regulatory activities
of neighboring TADs. The transcription factor CTCF
(CCTC-binding factor) typically binds in these regions
where it plays a pivotal role in the maintenance of bound-
aries. SVs can cause loss of function by disconnecting en-(D) Structural variants found in a cohort of unsolved adRP-affected fa
the genomic intervals for each SV used to analyze and annotate SV b
(E) Overview of all SV breakpoints identified in the RP17 locus. An ov
was identified (chr17: 57,499,214–57,510,765) and is highlighted by
partially shown for the purpose of this figure.
6 The American Journal of Human Genetics 107, 1–13, November 5,hancers from their target genes; however, disruption of
TAD structures and boundaries can also exert a gain-of-
function effect. Deletions, for example, can lead to the
fusing of two previously separated TADs (TAD-fusion), in-
versions can result in the exchange of regulatory material
between TADs (TAD-shuffling), whereas duplications can
give rise to the generation of novel domains, so-called
neo-TADs.12,13 In each case, SVs result in the generation
of ectopic contacts of enhancers with the promoters of
novel target genes resulting in aberrant gene activation.
The human limb malformations caused by SVs that alter
the CTCF-associated boundary of the WNT6/IHH/
EPHA4/PAX3 locus are a prominent example. The SVs
result in ectopic interactions between EPHA4 (MIM:
602188) limb enhancers and the neighboring develop-
mental genes that are normally insulated, driving ectopic
expression in the limb.14 Similarly, the deletion of a CTCF
site located between the Xist (MIM: 314670) and Tsix
(MIM: 300181) TADs on the X chromosome resulted in
a novel domain by fusion of the adjacent TADs (fused-
TAD).24 As a consequence, previously insulated en-
hancers activated genes in the adjacent TAD, leading to
the dysregulation of these genes.
Hi-C data were not available for human retina, and
therefore, we generated Hi-C maps of control human 3D
ROs to obtain maps of the chromatin organization of
our region of interest. Hi-C revealed a structured domain
containing YPEL2 (YPEL2 TAD) flanked by less structured
neighboring domains (Figure 3A). CTCF binding is pre-
sent on both boundaries (Figure 3B) supporting the TAD
structure at this locus. CTCF ChIA-PET data highlighted
interactions between the CTCF binding sites at the 50
and the 30 boundary of the YPEL2 TAD (Figure S7B).
Assay for transposase-accessible chromatin using seqenc-
ing (ATAC-seq) data from human retina show that the
chromatin in the YPEL2 TAD is accessible, and H3K27Ac
ChIP-seq data revealed that there are several active en-
hancers located within the YPEL2 TAD that are expected
to drive YPEL2 expression in the retina (Figure 3B).25
Importantly, the YPEL2 TAD harbors two regions of active
enhancers with binding sites for transcription factor (TFs)
known to be required for photoreceptor function,
including NRL, CRX, and OTX2 (Figure 3B). NRL is a TF
that is preferentially expressed in rod photoreceptors.
These TF binding sites correlated with H3K27Ac and
ATAC-seq peaks in retina. The published GeneHancer data-
set shows that these regulatory elements have interactions
with the YPEL2 promoter (Figure S7C).26 Collectively, these
analyses revealed that YPEL2 is located within an active
compartment that contains retinal-specific enhancers
(Figure 3C).milies; NL-SV5, UK-SV6, UK-SV7, and UK-SV8. Letters A–AI depict
reakpoints.
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Figure 3. YPEL2 is Located within a Structured Active Compartment that Contains Retinal-Specific Enhancers
(A) The TAD landscape of the genomic region disrupted by the RP17 SVs. Hi-C map of control retinal organoids revealed a structured
domain containing YPEL2.
(B) YPEL2 TAD boundaries correspond with CTCF sites identified in human retina. Analysis of RNA-seq and assay for transposase-
accessible chromatin using seqencing (ATAC-seq) data across the YPEL2 region shows YPEL2 retinal expression and an accessible chro-
matin configuration. Analysis of H3K27Ac ChIP-seq data in the same region revealed several active enhancers located within the YPEL2
TAD, which are enriched for retinal transcription factor binding sites, includingNRL, CRX, andOTX2.25 These enhancers were located 50
of the CTCF boundary site within LINC01476.
(C) Schematic representation of the YPEL2 TAD structure.
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Expression of YPEL2 and GDPD1 was assessed by qPCR
in multiple healthy human tissues, including retina
(Figure S8). YPEL2 is ubiquitously expressed in the tis-
sues studied, including retina, with highest relative
expression in brain. Single-cell retina RNA-seq datasets
revealed YPEL2 is expressed at higher levels in rod photo-
receptor cells, which is the primary cell type affected in
retinitis pigmentosa, compared to cone photoreceptors
(Figure S8).23 GDPD1 is detected at low expression inThe Amall tissue types but has higher expression in testis and
the brain. These data support the hypothesis that
YPEL2 expression is regulated by retinal enhancers
within the YPEL2 TAD.RP17 SVs Create New Topologically Associating
Domains and Ectopic Enhancer-Gene Interactions
Using the wild-type retinal organoid Hi-C map, we
modeled the TAD boundaries, CTCF site orientation, and
retinal TF binding site positions for each unique RP17 SVerican Journal of Human Genetics 107, 1–13, November 5, 2020 7
Figure 4. RP17 SVs Create Novel Domains (neo-TADs) and Hyper-activation of Retinal Enhancers
(A) Schematic modeling of the genome architecture spanning the RP17 region using Hi-C maps. The wild-type Hi-C map derived from
neuronal tissue shows a TAD with CTCF boundaries containing YPEL2 and retinal enhancers, flanked by unstructured domains. TAD
models of NL-SV1 and UK-SV2 (dotted vertical lines represent SV breakpoints) predict the formation of neo-TADs and ectopic interac-
tions of the retinal enhancer with GDPD1.
(B) Hi-C performed on retinal organoids (ROs) derived from control (top) and RP17 UK-SV2 individuals (bottom) (10 kb resolution; raw
count map). The chromatin organization in control ROs shows the YPEL2 TAD (indicated by dashed lines). Two novel domains (neo-
TAD 1 and 2) are visible in the UK-SV2 ROs, and neo-TAD 2 allows ectopic retinal enhancer contacts to GDPD1 and SMG8. The dashed
circle indicates the strong chromatin contact between retinal enhancers and the GDPD1 promoter.
(C) qPCR revealed significantly upregulated retinal enhancer RNA expression in UK-SV2 ROs compared to controls (n¼ 3, mean5 stan-
dard error of the mean, **p% 0.01).
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part of the YPEL2 TAD, the boundary to the neighboring
region and GDPD1. This results in the creation of a neo-
TAD that now contains the previously separated YPEL2 en-
hancers and GDPD1 in one domain. To directly investigate
the effect of the SVs in retinal cells, we reprogrammed
dermal fibroblasts from UK-SV2 to iPSC and differentiated
to 3D ROs, thus creating an in vitro model (Supplemental
Information). In this case, the duplicated regions are also
inverted. Hi-C of RP17 ROs (UK-SV2) revealed the creation
of two neo-TADs compared to control ROs (Figure 4B). The
rearrangement of CTCF sites caused by the SV creates
boundaries for two novel domains (neo-TAD 1 and 2)
where neo-TAD 2 contains a duplicated copy of GDPD1
and SMG8 and the retinal enhancers, confirming the
modeling for this SV (Figure 4A). Furthermore, on the basis
of our predictions, neo-TADs are created in each of the
RP17 cases and GDPD1 is predicted to gain ectopic access
to the retinal-specific enhancers (Figures 4A and S9). There-
fore, the potential convergent mechanism for retinal
degeneration is transcriptional activation and expression
of GDPD1 through juxtaposition of retinal TF binding sites
within active compartments bounded by CTCF sites. This
model would also fit with a dominant gain-of-function
mechanism of disease.
Next, we assessed retinal enhancer expression in control
and UK-SV2 ROs by enhancer RNA qPCR (Supplemental
Information). A significant increase of the retinal enhancer
was detected in RP17 ROs (Figure 4C), demonstrating that
this transcriptionally active retinal enhancer in the neo-
TAD could drive retinal expression of GDPD1.Differential Expression of GDPD1 in RP17 iPSC-Derived
Photoreceptor Precursors and 3D Retinal Organoids
Our experimental data and modeling predict GDPD1
enters a neo-TAD with retinal enhancers in all RP17
SVs. An extra copy of YPEL2 enters the neo-TAD of
NL-SV1, and SMG8 enters this domain in UK-SV2 (Fig-
ures 5 and S9).
To experimentally validate the consequence of RP17 SVs
in genomic and cellular context, we performed qPCR to
assess differential expression in PPCs (NL-SV1) and ROs
(UK-SV2). The expression of GDPD1, YPEL2, and SMG8
was compared to controls (Supplemental Information).
In both experimental models, the expression of GDPD1
was significantly increased compared to controls. YPEL2Figure 5. Convergent Mechanism of Ectopic Retinal Enhancer-GD
(A) In wild-type genomic context, YPEL2 expression in retina is driv
boring genes are insulated from retinal enhancer activation.
(B) The NL-SV1 duplication creates a neo-TAD with a full-length copy
specific enhancers to ectopically interact with GDPD1, which drives
(C) qPCR analysis of photoreceptor precursor cells (PPCs) revealed a
controls.
(D) The UK-SV2 duplication and inversion creates a neo-TAD with a
bounded by CTFC sites.
(E) qPCR analysis ROs revealed a significant upregulation ofGDPD1 ex
ROs, mean5 standard error of the mean, **p % 0.01, ****p% 0.000
10 The American Journal of Human Genetics 107, 1–13, November 5was increased in NL-SV1 only (Figure 5C), whereas SMG8
was increased in UK-SV2 (Figure 5E), which correlates
with our TAD modeling and Hi-C experimental data for
UK-SV2 ROs (Figured 5B, 5D, and S9). To further explore
the tissue-specific effect of this transcriptional upregula-
tion, we performed the same qPCR assays on fibroblasts
of the same individuals. None of these genes had increased
expression in affected individuals compared to controls
(data not shown).Discussion
Previous genetic studies of adRP-affected families mapping
to the RP17 locus have implicated missense variants in
CA4 as the cause of disease or have been unable to confirm
pathogenicity.7,8 Here, we describe the discovery of SVs as
the cause of adRP at the RP17 locus in a large number of
families, suggesting this is a previously unrecognized
major locus for adRP. Our results show how complex
rearrangements can result in the disruption of 3D genome
architecture, the re-wiring of enhancer-promoter interac-
tions, and consequent gene misexpression.
Following the identification of SVs in NL1 and UK1 via
short-read WGS, our search for similar complex SVs in
the RP17 genomic interval of genetically unexplained
adRP-affected families identified six other complex SVs
that segregated with disease. SVs are a major source of
normal variation in the human genome and are often
benign;27,28 however, none of the RP17 SVs are found in
the population database gnomAD29 or the Database of
Genomic Variants (DGV).30 Although overlapping canon-
ical SVs (deletions and duplications) have been identified,
they do not have breakpoints within the YPEL2-
LINC01476 region, as observed for all RP17 SVs reported
in this study. This is in line with observations that different
SVs can have different consequences depending on the
characteristics of specific SVs in local 3D chromatin and
epigenetic context.31,32
Base level resolution of breakpoint junctions and inter-
rogation of the DNA sequence signatures revealed the
mechanisms of the chromosomal rearrangements. Repeti-
tive elements are key factors in facilitating unequal cross-
over of genomic segments or providing microhomology
that induces fork stalling and subsequent template switch-
ing.33,34 Consistent with this model, repetitive elements
were present in the flanking sequences of breakpointPD1 Interaction Caused by RP17 SVs
en by retinal enhancers in a TAD with CTCF boundaries. Neigh-
of YPEL2, GDPD1, and the retinal enhancers. This enables retinal-
its misexpression.
significant upregulation of GDPD1 in NL-SV1 PPCs compared to
full-length copy of GDPD1 and SMG8 and the retinal enhancers
pression in UK-SV2 ROs compared to controls (n¼ 3 independent
1).
, 2020
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homology, and small insertions-deletions were found at all
breakpoints.34–36 Therefore, repetitive elements may
explain why the RP17 locus is prone to such structural vari-
ation, which is supported by the presence of breakpoint
‘‘hotspots,’’ as seen in LINC01476 intron 2 and YPEL2
intron 4; some breakpoints only differ by a small number
of base pairs (e.g., for UK-SV2 and UK-SV7).
None of the genes implicated in the RP17 SVs have been
previously associated with retinal disease. YPEL2 is ex-
pressed in retina, and single-cell RNA sequencing of human
and primate retina revealed expression in photoreceptors;
the highest expression was in rod photoreceptors.22,23
Although the function of YPEL2 in the retina is unknown,
we show that retinal expression is controlled by a number
of retinal TF binding sites, including NRL, which is predom-
inantly expressed in rod photoreceptors. Furthermore, Hi-C
data show thatYPEL2 and the retinal enhancer binding sites
are insulated from the surrounding region in a structured
YPEL2 TAD in control ROs and other tissues.
Hi-C analyses of UK-SV2 ROs revealed the generation of
neo-TADs, and altered structure and repositioning of the
boundaries enabled GDPD1 promoter-retinal enhancer
contacts and consequent GDPD1 misexpression in the
retina. The molecular disease mechanism in these cases is
similar to the reported duplications at the SOX9/KCNJ2
locus.13 As described for the rearrangements reported
here, the duplications at the SOX9 (MIM: 608160) locus
also encompass a regulatory domain (of SOX9), a boundary
(between the SOX9 and the KCNJ2 [MIM: 600681] TADs),
and the neighboring gene (KCNJ2). This results in the
formation of a neo-TAD containing the SOX9 regulatory
elements and the new target gene (KCNJ2) that are now
free to interact. In the SOX9 case, this leads to misexpres-
sion of KCNJ2 in a SOX9 pattern and consecutive limb
malformation, whereas in the RP-affected individuals,
the interaction of GDPD1 with YPEL2 enhancers leads to
misexpression in the retina. However, in some of the
RP-affected individuals, such as UK-SV2, the situation is
more complex because the duplications are inverted. In-
versions can lead to the exchange of regulatory material
from one end of the breakpoint to the other (also called
TAD-shuffling).12 In UK-SV2, the duplication creates two
neo-TADs, but the content is reorganized by the inversion.
Again, GDPD1 and retinal enhancers are brought together
in one new TAD. Thus, the pathogenetic principle remains
the same because all the RP17 SVs are predicted to create
new TADs allowing access of the retinal enhancers to
GDPD1. This suggests that increased expression of
GDPD1 in photoreceptors is the convergent mechanism
of disease. Consistent with this hypothesis, PPCs from
NL-SV1 and ROs from UK-SV2 showed significant
increased expression of GDPD1 in RP17-affected families
with different SVs compared to controls. In UK-SV2 ROs,
an increased expression of SMG8, which is also introduced
into the active neo-TAD of UK-SV2, was observed.
Conversely, YPEL2 shows upregulation in NL-SV1, whichThe Ameis in line with the complete duplication of YPEL2 in
NL-SV1. Importantly, qPCR provided evidence for the
increased expression of the retinal enhancer in UK-SV2
ROs and TF binding sites for NRL, which is preferentially
expressed in rod photoreceptors, the primary cell type
affected in RP.
Although increased expression of SMG8, YPEL2, or the
retinal enhancer cannot be excluded from contributing
to the phenotype in individual families, these experi-
mental data support the hypothesis of a convergent mech-
anism ofGDPD1 entry into the active neo-TADwith retinal
enhancers for all eight complex RP17 SVs. This is further
supported by the observation that the two affected individ-
uals in family UK13, who had an earlier age of onset and
more severe phenotype compared to all other families,
have a triplication (UK-SV6) where two copies of GDPD1
are predicted to enter the active neo-TAD.
Our data implicate increased retinal expression of
GDPD1 as a dominant gain-of-function mechanism lead-
ing to adRP. GDPD1 encodes a glycerophosphodiesterase,
which can hydrolyze lysophosphatidylcholine (lyso-PC)
to lysophosphatidic acid (LPA)37 with lysophospholipase
D (lysoPLD) activity on various lysophospholipids.38
GPDP1 is detected at low expression in the healthy retina,
and therefore, increased expression of GDPD1 could lead
to dysregulation of lipid metabolism, which is known to
be critical for photoreceptor function, although the exact
mechanisms of photoreceptor cell death are not
known.39–41 Disruption of lipid metabolism leading to
adRP, combined with the adult age of onset, opens avenues
for therapeutic intervention to preserve vision by restoring
lipid homeostasis.Data and Code Availability
Extensive data are presented in the Supplemental Informa-
tion to enable others to perform similar studies and
replicate our findings. WES and WGS data have not been
deposited in a public repository because of consent and
ethical considerations. Hi-C data are available on request.Supplemental Data
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 Figure S1: Agarose gels of of allele-specific breakpoint junction PCR amplications. PCR amplification 
of allele-specific breakpoints was performed, and gel electrophoresis was used for visualization. For 
each structural variant, allele-specific breakpoints (B) could be amplified in affected individual DNA (P) 
but not in DNA obtained from anonymous controls (C). Breakpoint junction nomenclature corresponds 
to those illustrated in Figure 2. Primer sequences used for PCR amplifcation are listed in Table S2. 
 Figure S2: Additional adRP families with structural variants within the RP17-locus. (A) Pedigrees of 
South African origin with structural variant 3 (SA-SV3) (B) Canadian family with structral variant 4 (CA-
SV4). (C) Dutch family (NL2) with structural variant 5 (NL-SV5), UK family (GC19255/GC1754) with 
structural variant 6 (UK-SV6), UK family (GC4344) with structural variant 7 (UK-SV7) and UK family 
(GC23464) with structural variant 8 (UK-SV8). WGS or WES was performed in individuals in blue or red, 
respectively.  
 Figure S3: Triplication of region in UK-SV6. Quantitative real-time PCR for individuals from family 
UK13, UK-SV6. Primer pairs qPCR 2 (first intron of GDPD1) and qPCR3 (downstream of YPEL2) 
confirmed triplication (four copies in the genome) of UK-SV6, compared to control unaffected DNA 
samples and additional control qPCR assays for genomic regions distal and proximal to this structural 
variant qPCR4 (last intron of LINC01476) and qPCR1 (exon 3 of SMG8). CTL, unaffected control DNA 
sample; UK-SV6, affected individual DNA sample. Primer sequences are listed in Table S3. 
  
  
Figure S4: Overview of all SV breakpoints identified in the RP17-locus. Breakpoints are indicated with 
dashed lines. Duplicated, triplicated or inverted genomic regions for each SV are illustrated with blue, 
dark blue or purple bars, respectively. An overlapping genomic region that is duplicated or triplicated 
in all SVs was identified (chr17:57,499,214-57,510,765) and is highlighted by a light-blue vertical bar. 
The size of DHX40 is reduced and CLTC is only partially shown in this figure.   
 Figure continues on next page 
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Figure S5: Assessment of microhomology at breakpoint sequences. (A-H) Breakpoint regions of 
structural variants (SVs) were assessed for presence of microhomology using multiple sequence 
alignment between the junction fragment and the 5’ and 3’ breakpoint regions using Clustal Omega. 
150 bp reference sequences flanking each side of the breakpoint were used as input. Regions of 
microhomology are indicated in red. Breakpoint annotation of genomic regions as illustrated in Figure 
2. 
  
 Figure S6: Detailed Retinal Imaging with Fundus Autofluorescence (FAF) and Optical Coherence 
Tomography (OCT). The blue arrow heads mark the temporal border of the ring of increased signal 
where present. The yellow arrow heads mark areas of cystoid macular edema (A, B, C). The orange 
arrow heads mark on the OCT scans the border of the residual ellipsoid zone (EZ). Bone spicules are 
visible in the mid periphery on FAF in cases (A, B, D). (A) Affected individual from family NL1 (NL-SV1). 
(B) Affected individual from family UK13 (UK-SV6). Affected individuals shown in (C) and (D) are from 
UK1 (UK-SV2). Two consecutive generations are shown, mother (C) and daughter (D). Note the slow 
structural disease progression indicated by these cases, with minimal change in the BCVA, due to 
sparing of the foveal EZ (orange arrow heads). The ring of increased signal decreases in size over time 
(blue arrow heads), with small areas of decreased signal (atrophy) developing and increasing in these 
same regions over time (green arrow heads). yr, years old; BCVA, best corrected visual acuity; LogMAR, 
Logarithm of the minimum angle of resolution. 
  
 Figure S7: CTCF sites insulate contacts within the YPEL2 TAD. (A) CTCF ChIP-seq data showed that 
YPEL2 is located within an insulated TAD that is present in multiple cell and tissue types, including 
human retina. (B) ChIA-PET CTCF interaction data established in K562 and MCF-7 cells revealed strong 
interactions between the CTCF binding sites on the 5’ side of the YPEL2 TAD, and the single CTCF 
binding site on the 3’ side of the YPEL2 TAD. (C) The structured YPEL2 TAD contains retina-specific 
enhancer elements as shown in Figure 3. These regulatory elements are also described in the 
Genehancer database1 and interactions with the YPEL2 promoter region were experimentally 
validated.  
  
 Figure S8: YPEL2 and GDPD1 expression across tissues and retinal cell types. (A) qPCR expression 
levels of YPEL2 across healthy human tissues. YPEL2 is ubiquitously expressed in the tissues studied, 
including retina, with highest expression in brain. (B) GDPD1 is detected at low levels in all tissue types, 
with higher levels of expression in brain and testis. (C-F) YPEL2 has higher levels of expression in rod 
photoreceptor cells compared to cones from single cell RNA sequence data. GDPD1 has low levels of 
expression in all photoreceptor cells. Single cell expression levels and plots were obtained from the 
Broad Institute Single Cell Portal, and is based on single cell RNA sequencing results of human2 (C-D) 
and macaque3 (E-F) retinal cell types. 
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 Figure S9: RP17-SVs are predicted to disrupt 3D chromatin organisation and create neo-TADs with 
ectopic retinal enhacer-gene contacts. Modelling of TAD boundaries, CTCF site orientation, gene 
position and orientation and retinal-specific enhancers for each unique RP17-SV is shown. Wild type 
chromatin organisation is depicted schematically, based on Hi-C maps. Schematic models of the 
genome architecture for each RP17-SV is shown above Hi-C map models (dotted vertical lines 
represent SV breakpoints). Shaded bars represent duplicated (black) or triplicated (grey) regions, 
whereas inversions are indicated by open bar below the TAD maps, with nomenclature corresponding 
to those described in Figure 2. In all RP17-SVs, new domains (neo-TADs) are created with ectopic 
contacts between retinal-specific enhancers and GDPD1. For NL-SV1, NL-SV5 and UK-SV6, an extra 
copy of YPEL2 is also introduced into the neo-TAD. For UK-SV2, SA-SV3, CA-SV4, NL-SV5, UK-SV7 and 
UK-SV8, one copy of SMG8 is introduced into the neo-TAD.  
  
 Table S1: Previously reported CA4 variants 
Genome cDNA Protein Ethnicity gnomAD AF 
all 
gnomAD AF 
subpopulation 
CADD_PHRED Detection method References 
g.58227429G>A c.4C>T p.Ala12Thr Chinese 0.000004471 
- 
(other EAS) 
6.280 
Targeted sequencing 
of CA4 
4 
g.58227435C>T c.40C>T p.Arg14Trp South-African 0.0002410 
0.0001368 
(AFR) 
15.94 
Locus gene 
sequencing (RP17) 
This study (SA1-4), 5, 6 
g.58234014G>A c.206G>A p.Arg69His Chinese 0.00004374 
0.0001087 
(other EAS) 
0.005 
Targeted sequencing 
of CA4 
7 
g.58235718C>A c.655C>A p.Arg219Ser 
Northern 
European 
0.00003186 
0.0001163 
(NWE) 
26.6 
Targeted sequencing 
of CA4 
6 
g.58235763G>A c.700G>A p.Val234Ile Spanish 0.01015 
0.01757 
(NWE) 
9.468 
Targeted sequencing 
of 12 adRP genes 
8 
Overview of CA4 (NM_000717.4) variants reported in literature. A CADD_PHRED score of ≥15 and allele frequency ≤0.0001 are considered as pathogenicity 
criteria. Values that meet these criteria are indicated in red. The p.Arg14Trp variant was found in families SA1-4 that are included in this study and carriers of 
SA-SV3. Genome, genomic position based on hg19; gnomad AF all, allele frequency in gnomAD v.2.1.1 database; gnomAD AF subpopulation, allele frequency 
in gnomAD v.2.1.1 based on subpopulation corresponding to the ethnicity of the affected individual in which the variant was reported in literature; 
CADD_PRED, Combined Annotation Dependent Depletion PHRED score; other EAS, other East Asian population; AFR, African population; NWE, Northwestern 
European population. 
  
Table S2: Primer sequences utilized to validate and characterize breakpoints 
Table continues on next page 
 
SV Breakpoint Coordinates F primer (5’-3’) R primer (5’-3’) Amplicon size (bp) 
NL-SV1 A-B 57,291,905 GCCTGGGTGACTAAGAAAGACTCCATTCCC CCACGGAGCACCTTGTAGCTCATTAACTGC 720 
B-B 57,518,137-57,291,905 GGCACTAATGAAACCAGAAAGACACTTGGC CCACGGAGCACCTTGTAGCTCATTAACTGC 839 
B-C 57,518,137 GGCACTAATGAAACCAGAAAGACACTTGGC TAGTCATAGTCCCTGATTCCCTTAAAGCGG 831 
UK-SV2 D-E 57,275,839 CATGACAAAACCCTGTCTCC CCTATCCAGTAAATGCCTCTTCC 881 
E-[G] 57,456,098-57,559,114 ATCAGGCAACACGACACCAT AGAGTGTTAACAAAGTAGACTCGAT 1262 
[G]-[F] 57,468,960 GGAGCCTGAAGGAGTTGTCAAA AATCCAACACATCTTCAGGGCA 999 
[F]-[E] 57,456,098 ATCAGGCAACACGACACCAT TCTTCCACATGGGGACATAGG 894 
[E]-G 57,275,839-57,468,960 CCTATCCAGTAAATGCCTCTTCC AATCCAACACATCTTCAGGGCA 1427 
G-H 57,559,114 AGAGTGTTAACAAAGTAGACTCGAT ACTGGCCAAAGAAAGACCCT 989 
SA-SV3 I-J 57,247,615 GGGTGCAGTCATTCATTCCT TCTCTTGAGCCCAGGAAATC 513 
J-K 57,391,678 TCATGTGAAATGCCACCTTC GAGTGTAACGGCATGGTCTC 1530 
K-L 57,499,214 TTCTTTTAAGGGGGACCTTG AAGCCAAGATCATCCAAACC 694 
L-J  57,516,678-57,247,615 TGCCACTTTCCATATGTGTG TCTCTTGAGCCCAGGAAATC 657 
J-[M] 57,391,678-57,612,711 TTATGAATCTGCCCAAGATCAC AATGATTTGCCTTGGCTTTC 1022 
[M]-L [57,516,678]-57,499,214 GAATTTGCTTGAAGGGCTTG AAGCCAAGATCATCCAAACC 486 
L-M 57,516,678 TGCCACTTTCCATATGTGTG GAATTTGCTTGAAGGGCTTG 702 
M-N 57,612,711 AATGATTTGCCTTGGCTTTC CAATGCCATACTCTGGACACC 823 
CA-SV4 O-P 57,233,035 GAAGAGCCAACCAATCACAC AACAGGCCCAGCTACTCAAG 368 
P-[R] 57,280,008-[57,634,900] ATACAGGGAGACCCCGTTTC CTGATCGAAGTGCAAAATGG 1801 
[R]-[Q] 57,483,883 CTACACAGGGGACTGACACC CAGCAGCAGCATTATCAACC 677 
[Q]-[P] 57,280,008 ATACAGGGAGACCCCGTTTC AGATGAGTTCTTGCTCTGTTGC 653 
[P]-R [57,233,035]-57,483,883 CAGCAGCAGCATTATCAACC AACAGGCCCAGCTACTCAAG 493 
R-S 57,634,900 CTGATCGAAGTGCAAAATGG TGGAGGGAAGGTTATCTTGG 2299 
NL-SV5 T-U 57,260,511 TTCATCATCCACCACCTCCT TCCATGGACTCCCTGAAACT 893 
U-U 57,515,862-57,260,511 TTGCACCGCTGTTAAGAAAG GAAGAGGAGACCCCAAAATG 648 
U-V 57,515,862 CCGCTGTTAAGAAAGGCTCT CCCACCTCAAGGAGCTTGTA 971 
UK-SV6 W-X 57,295,969 TAAGGGATTCCAGGAACTTAAATG AAAATTTGCCAGGGGTGG 767 
X-X 57,510,765-57,295,969 TGAGAGAGCTGGAGGCTAGT AAAATTTGCCAGGGGTGG 1295 
X-Y 57,510,765 TGAGAGAGCTGGAGGCTAGT AGCAACTGCAACTGAACTCCT 1013 
UK-SV7 Z-AA 57,259,525 TCTTCCGTATCTCTGTCCTCAG TGGGAGCTCAAGTGGACAAC 1097 
 AA-[AC] 57,453,630-57,710,821 GCTGGGACTCAGAGGGTGTT AAGCATCTAGGGCACATCCT 1554 
 [AC]-[AB] 57,468,931 GGAGCCTGAAGGAGTTGTCAAA AATCCAACACATCTTCAGGGCA 999 
 [AB]-[AA] 57,453,630 GCTGGGACTCAGAGGGTGTT AACAGTCATGGCTCACACTCA 1200 
 [AA]-AC 57,259,525-57,468,931 TGGGAGCTCAAGTGGACAAC AATCCAACACATCTTCAGGGCA 1504 
 AC-AD 57,710,821 AAGCATCTAGGGCACATCCT ACCCTATACTGAGGGACCTGC 990 
SV, Structural variant; Breakpoint, Breakpoints between genomic regions as illustrated in Figure 2; Coordinates, genomic positions of breakpoints according 
to hg19; F primer and R primer, primer sequences used for PCR amplification and Sanger sequencing; Amplicon size, size of amplified PCR product in base 
pairs (bp). [] indicates inverted segments. Allele-specific mutant breakpoint junctions are indicated in bold.  
 
 
 
  
SV Breakpoint Coordinates F primer (5’-3’) R primer (5’-3’) Amplicon size (bp) 
UK-SV8 AE-AF 57,277,347 GCTGACACTTTCCACCCC CCAATGCAAAACCTGATACAGT 551 
 AF-[AH] 57,326,234-57,631,659 TGGGGATGTTCTGCTAAGGG TGCCTGTAGTCCAATTTCTCAG 458 
 [AH]-[AG] 57,413,153 CAGTGGTGTGATCTGCTCA CACCAAGCATTTTCAGCAGC 478 
 [AG]-[AF] 57,326,234 TGGGGATGTTCTGCTAAGGG TGTGCCCAGCCCTTTTCATT 525 
 [AF]-AH 57,277,347-57,413,153 CCAATGCAAAACCTGATACAGT CACCAAGCATTTTCAGCAGC 569 
 AH-AI 57,631,659 TGCCTGTAGTCCAATTTCTCAG GTGTGGGAAGGGTTGCTTAT 433 
Table S3: qPCR primers 
Target Primer Oligonucleotides (5’-3’) 
SMG8 exons 3-4, mRNA Forward ACTAATGCCTCAGGTTCAGC 
 Reverse ATCTCAAAACCCAAAGGCCA 
GDPD1 exons 3-5, mRNA Forward ATACTGTGAGCTCCCACCTTAC 
 Reverse GGAGTGTTAGGAAAGGCCTCAA 
YPEL2 exons 2-4, mRNA Forward TCACTGCAGAGCTCACTTGG 
 Reverse CCACAGCCCACATTAACTACTGA 
TRIM37 exons 11-12, mRNA Forward GCGTCAGAGAGCAGATCC 
 Reverse GCACAACTCCATTTCCATCTG 
NRL exons 3-3, mRNA Forward GGCTCCACACCTTACAGCTC 
 Reverse AGCCAGTACAGCTCCTCCAG 
CRX exons 2-3, mRNA Forward  GCCCCACTATTCTGTCAACG 
 Reverse CTTCAGAGCCACCTCCTCAC 
ACTB exons 3-4, mRNA Forward CCAACCGCGAGAAGATGA 
 Reverse CCAGAGGCGTACAGGGATAG  
GUSB exons 2-3, mRNA Forward AGAGTGGTGCTGAGGATTGG 
 Reverse CCCTCATGCTCTAGCGTGTC 
Retinal enhancer, eRNA Forward ACCTGCCTGTACGAATCCAA 
 Reverse CTGGGAGGAGGCAAATTGTA 
   
SMG8 exon 4 Forward CCTGGAAAGAGAAGTGCGGT 
Triplication qPCR 1 Reverse AGGCCCAGAGCACATGAATC 
GDPD1 intron 1 Forward TGTGAATTGAGGGCTCTTCCG 
Triplication qPCR 2 Reverse ACCGTGTCTTTCCCGTTTCA 
Downstream of YPEL2 Forward AAGGTCAGCGTTCTCTCAGAAG 
Triplication qPCR 3 Reverse TGTTGAGTTCTGTCTGCCTCG 
LINC01476 intron 2 Forward CCTGCAACCTAACCCTAAGC 
Triplication qPCR 4 Reverse GCATGCCAGATCGCTGTTG 
  
Table S4: Shared heterozygous variants (MAF ≤0.0001, 3 affected individuals) located within the 
Dutch RP17-locus (NL1)  
Chr Start End Ref Var gnomAD_G AF Component Gene name 
chr17 55225642 55225642 G C . intergenic 
 
chr17 55518925 55518925 C T . intronic MSI2 
chr17 55625150 55625150 C T . intronic MSI2 
chr17 55645018 55645018 G A . intronic MSI2 
chr17 55774511 55774511 A T . intergenic 
 
chr17 55774518 55774518 C T . intergenic 
 
chr17 55815842 55815842 C A . intergenic 
 
chr17 55875136 55875136 C A . ncRNA_intronic 
 
chr17 56372707 56372707 T A . intergenic 
 
chr17 56726598 56726598 G C . intronic TEX14 
chr17 56769489 56769489 G C 0.00008155 upstream TEX14 
chr17 56811950 56811950 T 
 
. UTR3 RAD51C 
chr17 56878006 56878006 C T . intronic PPM1E 
chr17 56970337 56970337 G T . intronic PPM1E 
chr17 56970342 56970342 A T 0.00006367 intronic PPM1E 
chr17 56970349 56970349 A C . intronic PPM1E 
chr17 56970362 56970362 G A . intronic PPM1E 
chr17 57232150 57232150 C G . intronic SKA2 
chr17 57315768 57315774 TTATTTT 
 
. intronic GDPD1 
chr17 57333198 57333198 
 
TG . intronic GDPD1 
chr17 57403137 57403137 
 
T . intergenic 
 
chr17 57482817 57482817 A T . upstream AC091059.1 
chr17 57510654 57510654 A T . ncRNA_intronic 
 
chr17 57717126 57717126 C T . intronic CLTC 
chr17 57788781 57788783 ACT 
 
. intronic VMP1 
chr17 57788784 57788784 C T . intronic VMP1 
chr17 57812263 57812263 
 
TT . intronic VMP1 
chr17 57827828 57827828 
 
C 0.00003192 intronic VMP1 
chr17 58092315 58092315 T C . ncRNA_intronic 
 
chr17 58093706 58093706 A C . ncRNA_intronic 
 
chr17 58203846 58203846 G A . upstream AC025048.5 
chr17 58691382 58691382 T C . intronic PPM1D 
chr17 59551786 59551796 CTACCAGCATT 
 
. intronic TBX4 
chr17 59646261 59646261 G T . intergenic 
 
chr17 59652939 59652939 A T . intergenic 
 
chr17 59654667 59654667 A T . intergenic 
 
chr17 59935737 59935737 T G . intronic BRIP1 
chr17 59987185 59987192 TGTGTGTG 
 
. intronic INTS2 
chr17 60065110 60065110 A T . intronic MED13 
chr17 60223074 60223074 G C . intergenic 
 
chr17 60223078 60223078 G T . intronic 
 
Chr; chromosome, Start, End; genomic positions based on hg19, Ref; reference allele, Var; variant, 
GnomAD_G AF; minor allele frequency according to gnomAD v.2.1.1, Component; genomic position.   
Table S5: Shared heterozygous variants (MAF ≤0.0001, 3 affected individuals) located in the 
founder haplotype in family UK1 
Chr Start End Ref Var gnomAD_G AF Component Gene name 
chr17 56059537 56059537 T C 0.00003228 intronic VEZF1 
chr17 56122144 56122144 T C 0.00003228 intergenic 
 
chr17 56293716 56293716 G A . intronic MKS1 
chr17 56478605 56478605 T C . intronic RNF43 
chr17 56731111 56731111 G A . intronic TEX14 
chr17 56775478 56775478 T A . intronic RAD51C 
chr17 56783547 56783547 T C . intronic RAD51C 
chr17 56834462 56834462 C A . intronic PPM1E 
chr17 57107553 57107553 G A . intronic TRIM37 
chr17 57260755 57260755 A G 0.0001 intronic PRR11 
chr17 57548764 57548764 T C . ncRNA_intronic LINC01476 
chr17 57616479 57616479 A G 0.00009681 intergenic 
 
chr17 57641653 57641653 G A 0.000097 intergenic 
 
chr17 57688592 57688592 T C . intergenic 
 
chr17 57918969 57918969 G C . UTR3 VMP1 
chr17 58024808 58024808 A G . UTR3 RPS6KB1 
chr17 58108605 58108605 G A . intergenic 
 
chr17 58932373 58932373 C T . intronic BCAS3 
chr17 59279276 59279276 C T 0.00006532 intronic BCAS3 
chr17 59328755 59328755 C A . intronic BCAS3 
chr17 59913924 59913924 C T . intronic BRIP1 
chr17 60391209 60391209 G A 0.0001 intergenic 
 
chr17 60404484 60404484 C G 0.0001 intergenic 
 
chr17 60428327 60428327 G T . intergenic 
 
chr17 61687237 61687237 C T 0.00003228 intergenic 
 
chr17 61696765 61696765 T A 0.00006906 intergenic 
 
chr17 62009718 62009718 C T 0.00009688 upstream CD79B 
chr17 62075612 62075612 A G . ncRNA_intronic PRR29-AS1 
chr17 62113494 62113494 C G . intergenic 
 
chr17 62826064 62826064 A C . ncRNA_intronic PLEKHM1P1 
chr17 62834157 62834157 C G . upstream PLEKHM1P1 
chr17 62855508 62855508 G A 0.0001 intronic LRRC37A3 
Chr; chromosome, Start, End; genomic positions based on hg19, Ref; reference allele, Var; variant, 
GnomAD_G AF; minor allele frequency according to gnomAD v.2.1.1, Component; genomic position. 
  
Table S6: Genomic details of RP17-SVs 
SV Type Chr Start End Event Size (Mb) Genomic regions Genes involved Detection method 
NL-SV1 Dup 17 57,291,905 57,518,137 Dup 0.23 B SMG8, GDPD1, YPEL2, MIR4729, LINC01476 FreeC, Manta 
UK-SV2 DupINVdup 17 57,275,839 57,456,098 Dup 0.18 E PRR11, SMG8, GDPD1, YPEL2, MIR4729 Canvas 
   57,275,839 57,559,114 Inv 0.28 E, F, G PRR11, SMG8, GDPD1, YPEL2, MIR4729, 
LINC01476 
Manta 
   57,468,960 57,559,114 Dup 0.09 G YPEL2, LINC01476 Canvas 
SA-SV3 DupINVdup 17 57,247,615 57,391,678 Dup 0.14 J PRR11, SMG8, GDPD1 FreeC 
   57,516,678 57,612,711 Inv 0.10 M LINC01476 Manta 
   57,499,214 57,612,711 Dup 0.11 L, M LINC01476 FreeC 
CA-SV4 DupINVdup 17 57,233,035 57,280,008 Dup 0.05 P PRR11 FreeC 
   57,233,035 57,634,900 Inv 0.40 P, Q, R PRR11, SMG8, GDPD1, YPEL2, MIR4729, 
LINC01476 
Manta 
   57,483,883 57,634,900 Dup 0.15 R LINC01476 FreeC 
NL-SV5 Dup 17 57,260,511 57,515,862 Dup 0.13 U PRR11, SMG8, GDPD1, YPEL2, MIR4729, 
LINC01476 
FreeC, Manta 
UK-SV6 Trip 17 57,295,969 57,510,765 Trip 0.21 X GDPD1, YPEL2, MIR4729, LINC01476 Canvas, Manta 
UK-SV7 DupINVdup 17 57,259,525 
57,259,525 
 
57,468,931 
57,453,630 
57,710,821 
 
57,710,821 
Dup 
Inv 
 
Dup 
0.16 
0.42 
 
0.24 
AA 
AA, AB, AC 
 
AC 
PRR11, GDPD1, YPEL2, MIR4729 
PRR11, GDPD1, YPEL2, MIR4729, LINC01476, 
DHX40, CLTC 
YPEL2, LINC01476, DHX40, CLTC 
Canvas 
Manta 
 
Canvas 
UK-SV8 DupINVdup 17 57,277,347 57,326,234 Dup 0.05 AF PRR11, SMG8, GDPD1 Canvas 
   57,277,347 57,631,659 Inv 0.35 AF, AG, AH PRR11, GDPD1, YPEL2, MIR4729, LINC01476  Manta 
   57,413,153 57,631,659 Dup 0.22 AH YPEL2, MIR4729, LINC01476 Canvas 
SV, Structural variant; Type, complex structural rearrangements specified as duplications (dup), inversions (inv), triplications (trip) rearrangements; Start, End, 
genomic positions of structural rearrangements according to GRCh37/hg19; Size, of structural rearrangement in Mb; Genomic regions annotated as illustrated 
in Figure 2; Detection method, specific tools employed for identification of structural rearrangements are described in materials and methods section. 
  
Table S7: Repetitive elements identified in sequence flanking the breakpoints  
SV Breakpoint Coordinates Repetitive elements 
NL-SV1 A-B 57,291,905 97.01% SINE/ALU 
 B-C 57,518,137 24.92% SINE/MIR 
UK-SV2 D-E 57,275,839 99.34% SINE/ALU 
 E-F 57,456,098 16.28% SINE/ALU 
 F-G 57,468,960 44.19% SINE/ALU 
 G-H 57,559,114 46.18% SINE/ALU 
SA-SV3 I-J 57,247,615 54.49% SINE/ALU, 39.53% DNA 
 J-K 57,391,678 85.86% SINE/ALU 
 K-L 57,499,214 22.92% SINE/ALU 
 L-M 57,516,678 55.15% SINE/ALU, 14.29% DNA/hAT-Charlie 
 M-N 57,612,711 50.17% SINE/ALU, 20.27% small RNA 
CA-SV4 O-P 57,233,035 NP 
 P-Q 57,280,008 25.58% SINE/ALU 
 Q-R 57,483,883 NP 
 R-S 57,634,900 96.01% LTR/ERV-class I 
NL-SV5 T-U 57,260,511 NP 
 U-V 57,515,862 50.17% SINE/ALU, 38.21% LINE/L1 
UK-SV6 W-X 57,295,969 72.76% SINE/ALU 
 X-Y 57,510,765 81.06% SINE/ALU 
UK-SV7 Z-AA 
AA-AB 
AB-AC 
AC-AD 
57,259,525 
57,453,630 
57,468,931 
57,710,821 
95.68% SINE/ALU 
67.11% SINE/ALU 
33.22% SINE/ALU 
66.45% SINE/ALU 
 
UK-SV8 AE-AF 57,277,347 NP 
 AF-AG 57,326,234 NP 
 AG-AH 57,413,153 68.44% SINE/ALU 
 AH-AI 57,631,659 41.86% SINE/ALU, 56.48% LINE/L1 
Presence of repetitive elements was assessed using RepeatMasker from the reference sequence, 150 
bp reference sequences flanking each side of the breakpoint were used as input. SV, Structural variant; 
Breakpoint, Breakpoint annotation of genomic regions as illustrated in Figure 2; Coordinates, Genomic 
position of breakpoint according to GRCh37/hg19 coordinates; Repetitive elements. Percentage of 
repetitive elements present in input sequence per specified element (class/family); NP, Not present. 
Table S8: Assessment of microhomology, insertions and deletions at allele-specific breakpoints 
SV Breakpoint junction 3’ Coordinates 5’ Coordinates (Micro)homology Insertion Deletion 
NL-SV1 B-B 57,518,137 57,291,905 5 bp (AGGCA) - - 
UK-SV2 E-[G] 57,456,098 57,559,114 NP 9 bp (TTTTATGAC) - 
 [E]-G 57,275,839 57,468,960 NP 9 bp (AGGCTGGTC) - 
SA-SV3 L-J 57,516,678 57,247,615 NP 23 bp (AAAAAAAACTTGAAAAAGAAGTT) - 
 J-[M] 57,391,678 57,612,711 4 bp (TCAG) - - 
 [M]-L 57,516,678 57,499,214 1 bp (C) 13 bp (GGTCCAGATTGTG) 4 bp (AGAG) 
CA-SV4 P-[R] 57,280,008 57,634,900 1 bp (T) - - 
 [P]-R 57,233,035 57,483,883 2 bp (GC) 5 bp (TAAGC) - 
NL-SV5 U-U 57,515,862 57,260,511 5 bp (ATCCT) - - 
UK-SV6 X-X 57,510,765 57,295,969 >100 bp - - 
UK-SV7 AA-[AC] 57,453,630 57,710,821 >100 bp - - 
 [AA]-AC 57,259,525 57,468,931 NP 10 bp (GTAATTTTTC) - 
UK-SV8 AF-[AH] 57,326,234 57,631,659 NP 2 bp (CT) - 
 [AF]-AH 57,277,347 57,413,153 2 bp (CT) - - 
SV, Structural variant; Breakpoint junction, Allele-specific breakpoint junction between genomic regions as illustrated in Figure 2; Coordinates, genomic 
position of breakpoints according to hg19; Microhomology, presence of microhomology was assessed using ClustalOmega; Insertion and deletion, presence 
of insertions or deletions as determined by Sanger sequencing. [ ] Indicate inverted segments, bp, base pairs; NP, not present. 
 
 
  
 Table S9: Clinical findings  
 SUPPLEMENTAL MATERIALS AND METHODS 
SNP genotyping 
The RP17-locus was previously established using polymorphic markers selected from the Généthon 
genetic map, that were genotyped in 23 individuals from index family NL1.9 Subsequently, we collected 
DNA from 27 individuals (18 affected and 9 unaffected subjects) from the fourth generation of the 
family. SNP-genotyping was performed on these 27 DNA samples from generation four, and for 36 
individuals (17 affected and 10 unaffected subjects and 9 spouses) from the second and third 
generation using the HumanCore-24V.1.0 array (Illumina). The RP17-locus was further refined by 
determining phase in a two-parent-sib dataset. 
 
Exome and Genome sequencing 
Index family NL1; Whole exome sequencing (WES) was performed for three affected individuals from 
different branches of the family. Exome enrichment was performed using the Aligent SureSelect 
Human All Exome V5 kit following manufacturer’s instructions. Subsequently, WES was executed on 
an Illumina HiSeq2000TM system by BGI Europe (Copenhagen, Denmark). BWA V.0.7810 and GATK 
HaplotypeCaller V.3.311 were used for read mapping along the hg19 reference genome (GRCh37/hg19) 
and variant calling, respectively. Variants were annotated using an in-house developed pipeline.  
 
WGS was performed by BGI (Hongkong, China) on a BGISeq500 using a 2x 100 bp paired end module, 
with a minimal median coverage per genome of 30-fold. SVs were called using Manta Structural Variant 
Caller V.1.1.0 (Illumina; paired end and split read evidence for SVs) and copy number variants (CNVs) 
using Control-FREEC (detection of copy number changes and allelic imbalances based on read depth).12 
Variants were validated and visualized using the IGV software (V.2.4).13 Shared single nucleotide 
variants (SNVs) or SVs located in or spanning the refined RP17-locus were assessed for putative 
pathogenicity. Variants were prioritized based on a minor allele frequency (MAF) ≤0.0001 in gnomAD.14  
 
 Index family UK1; WES was performed for one affected individual as previously described.15 WGS was 
subsequently performed for four affected individuals from distant branches of the family by Edinburgh 
Genomics using TruSeq Nano with a minimal median coverage of 30-fold per genome. Variants were 
assessed and filtered using the Variant Annotation and Filter Tool (VarAFT).16 Variants were prioritized 
based on a MAF ≤0.0001 in gnomAD. CNVs and SVs were analyzed from WES data using ExomeDepth17 
and WGS data using Canvas Copy Number Variant Caller18 (Illumina; copy number gain or loss based 
on read depth) and Manta Structural Variant Caller.19 
 
For additional unsolved adRP families, or families suspected to harbor RP17-SVs, WES or WGS was 
performed. Families of Canadian (CA) or South African (SA) origin were analyzed in the Netherlands 
with additional families of Dutch origin. WGS was performed as described for NL1. For UK families, 
WGS was executed as described for UK1 or through the NIHR-Bioresource and Genomics England 
pipelines as previously described.15; 20  
 
Characterization and validation of structural variants 
Primer sequences and coordinates are listed in Table S2 and PCR conditions for all breakpoint 
junctions are available upon request. 
 
SV breakpoint regions were assessed for presence of microhomology and repetitive elements. 
Breakpoint regions and junctions were defined as 150 bp flanking sequence surrounding the 
breakpoint, which were used as input sequences for subsequent analyses. The presence of 
microhomology at the breakpoints was assessed using multiple sequence alignment between the 
junction fragment and the 5’ and 3’ breakpoint regions using Clustal Omega.21 The presence of 
repetitive elements at the breakpoint regions was assessed using RepeatMasker.22 
 
 To validate the presence of a triplicated region for UK-SV6, a quantitative real-time PCR (qPCR) 
experiment was performed on genomic DNA from affected individuals from family UK13 (n=2), and 
unaffected controls (n=2). qPCR was performed using SYBR Green labTAQ Green mix (labTAQ) on a 
QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). Primer pairs were designed to amplify 
genes in the suspected triplicated regions and distal and proximal regions on Chr17 outside the 
triplicated areas as a reference for standard quantity. Primer sequences and chromosomal positions 
are listed in Table S3.  
 
Each reaction was run in triplicate and was comprised of 2x labTAQ Green mix (labTAQ), 0.8 µl of each 
primer (10 mM) and 25 ng DNA in a final reaction volume of 20 µl. Cycling conditions were as follows: 
95°C for 2 min, followed by 40 cycles at 95°C for 15 s and 60°C for 20s. Dissociation curves were 
generated by heat denaturation over a temperature gradient from 60–95°C to ensure no primer-
dimers had formed and to check for a single amplicon. To verify the presence of a single PCR product, 
samples were also electrophoresed on a 2% agarose gel. Data were obtained using the QuantStudioTM 
Real-Time PCR Software (Applied Biosystems) to generate an amplification plot and a melting curve 
for each reaction. The fold difference of the target region was normalized to the wild type reference 
genomic region with respect to the calibrator sample, and was calculated using the ΔΔCt method.23  
 
Interrogation of the genomic region 
Available Hi-C, ChIP-seq and RNA-seq datasets were downloaded, analyzed and visualized using UCSC 
genome browser.24 Human retina ChIP-seq and RNA seq datasets were obtained from Cherry et al. 
2020.25 CTCF ChIP-seq datasets for GM12878 and K562 were retrieved from the ENCODE project/Broad 
Institute26 and for MCF-7 from the ENCODE project/University of Washington.27 CTCF ChiA-PET libraries 
for K562 and MCF-7 (GSM970215) were obtained from the ENCODE/GIS-Ruan dataset.28 
 
 
 Reprogramming fibroblasts into iPSCs and differentiation into photoreceptor progenitor cells  and 
3D retinal organoids 
Fibroblasts were cultured from skin biopsies of individuals with NL-SV1, UK-SV2, and anonymous 
control individuals. Cell lines were reprogrammed into iPSCs and differentiated in PPCs (NL-SV1) or ROs 
(UK-SV2). 
 
For NL-SV1, fibroblasts of two affected and four anonymous control individuals were reprogrammed 
into iPSCs. Reprogramming into iPSCs was performed by lentiviral transduction as previously 
described29, for one control cell line, reprogramming was performed using episomal vectors 
(Addgene).30 iPSC lines for each affected and control individual were then differentiated into PPCs 
following the previously described 60-day protocol.29; 31 For each iPSC line, differentiation was 
performed for two iPSC clonal lines in triplicate. Differentiation of PPCs was confirmed by RT-qPCR for 
neural (PAX6) and photoreceptor progenitor (CRX and NRL) markers (data not shown). 
 
For one affected individual with UK-SV2 and one control individual, fibroblasts were reprogrammed 
into iPSCs using episomal vectors (Addgene), as described previously.30 Retinal organoids were 
differentiated from iPSC, following a previously described protocol with slight modifications.32 iPSCs 
were seeded on plates coated with Geltrex (ThermoFisher Scientific) until neuronal retinal vesicles 
(NRVs) appeared. NRVs were excised by a sterile scalpel and distributed in single wells in 25 wells low-
attachment plates. NRVs were than cultured in Retinal differentiation media; 3:1 v/v of DMEM:F12, 
2% B27 supplement, 1% Non-Essential Amino Acid, 1% Penicillin-Streptomycin (Gibco) for one week. 
Optic vesicles were then cultured in Retinal Maturation Medium 1 (3:1 v/v of DMEM : F12, 2% B27 
supplement, 1% Non-Essential Amino Acid, 1% Penicillin-Streptomycin, 10% Fetal Bovine Serum 
(Labtech), 100 µM Taurine, 2 mM GlutaMAX) until day 70, then changed to Retinal Maturation Medium 
2 (3:1 v/v of DMEM : F12, 1% N2 supplement, 1% Non-Essential Amino Acid, 1% Penicillin-
Streptomycin, 10% Fetal Bovine Serum (Labtech), 100 µM Taurine, 2 mM GlutaMAX) until maturation 
 and collection of the ROs for experimental procedures. Media was supplemented with 1 µM retinoic 
acid from day 50 to day 70, then changed to 0.5 µM from day 70 to day 100. After day 100 no further 
supplement was added to the media. 
 
Preparation of low input Hi-C libraries (Low-C)  
Four UK-SV2 and four control 200-day old ROs were harvested and dissociated to single cells by 
gentle trituration in 150 µL PBS. Total volume was brought up to 500 µL with PBS before fixation with 
2% PFA/PBS for 10 min while tumbling. Next, 100 µL of 1.425 M glycine were added and incubated in 
rotation for 5 min. To quench the cross-linking reaction, cells were placed on ice for 10 min. Then, 
cells were centrifuged for 8 min at 500 g and 4 ˚C, and supernatant was removed. The pellet was 
resuspended in cold lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1.15 
Triton X-100, 5% Protease inhibitor cocktail) and incubated for 15 min on ice. Cells were centrifuged 
for 5 min at 500 g and 4 ˚C, and the supernatant was discarded. Finally, lysed cells were washed in 
500 µL PBS and centrifuged for 2 min at 500 g and 4 ˚C. Cells were snap frozen in liquid N2 before 
restriction enzyme digestion. Next, RO fixed chromatin (2x105 cells) from UK-SV2 and controls was 
digested for 2h at 37 ˚C with a 4bp cutter (DpnII; New England Biolabs - NEB). The DNA overhangs 
generated by the restriction enzyme were marked with biotin-14-dATP (Thermo Fischer Scientific) 
and the proximity ligation step was performed for 4 h at 18 ˚C using T4 DNA ligase (NEB). Crosslink 
reversal was performed overnight at 65 ˚C with vigorous shaking (1,000 rpm). The DNA was 
precipitated by adding Phenol-Chloroform-Isoamyl alcohol mix (25:24:1) (Merck) and then sheared to 
fragments of 300-600 bp using Covaris S220 (2 cycles, each 50sec long; 10% duty; 4 intensity; 200 
cycles/burst). The biotin-filled DNA fragments were pulled down using Dynabeads MyOne 
Streptavidin T1 beads (Thermo Fischer Scientific) and the products were prepared for Illumina short-
reads sequencing using the NEBNext Ultra DNA Library Prep kit (NEB). 
 
 
 Quantitative real time PCR of genes and enhancer RNA within the RP17-locus  
Expression of genes located in the RP17-locus was assessed using RT-qPCR in human tissues, affected 
individual and control PPCs and ROs. Commercially available RNA panels were used to determine the 
expression of GDPD1 and YPEL2 in healthy human adult tissues. RNA isolation and cDNA preparation 
were performed as previously described.33 Single cell RNA sequencing data of human2 and primate 
retinal cell types3 was obtained and visualized using the Broad Institute Single Cell Portal. 
 
For the PPCs, total RNA was extracted using a Nucleospin RNA kit (Machery-Nagel) and cDNA was 
synthesized using an iScript cDNA synthesis kit (Bio-Rad). qPCR analysis was performed using GoTaq 
qPCR Master Mix (Promega) following manufacturer’s instructions. 100 day old ROs were harvested 
and RNA was extracted using RNeasy Mini Kits (Qiagen). cDNA was synthesized using Tetro cDNA 
Synthesis kits (Bioline) and qPCR analysis was performed using the SYBR Green labTAQ Green mix 
(labTAQ) following manufacturer’s instructions on a QuantStudio 6 Flex Real-Time PCR System (Applied 
Biosystems). 
 
Primers were designed to assess differential expression of genes implicated in the SVs, and control 
reference genes and retinal progenitor genes (Table S3). Primers to detect retinal enhancer expression 
were designed based on observed transcriptional activity of the enhancer RNA in the FANTOM5 Cap 
Analysis of Gene Expression (CAGE) human dataset (Table S3).34 Relative gene expression levels, 
compared to the reference genes GUSB and ACTB, were determined with the ΔΔCt method.23 
Statistical analyses were performed using an unpaired Student t-test to test for significance between 
groups. 
 
 
 
 SUPPLEMENTAL TEXT 
RESULTS 
Refinement of the RP17-locus in two unrelated adRP families 
Index family NL1; In total, 35 affected and 28 unaffected individuals were included. Assuming complete 
penetrance of the phenotype, a refined locus of 5.16 Mb was identified; chr17:g.55,112,092-
60,271,924 (rs8078110-rs9910672) (Figure 1D), with a maximum LOD-score of 15.0. Next, WES was 
performed in three affected family members from different branches of the family. No rare coding or 
splice site heterozygous variants (MAF ≤0.0001) located within the defined locus were identified that 
were shared by all three individuals. In addition, no rare shared heterozygous variants were found in 
IRD-associated genes (RetNet). Subsequently, WGS was performed in three additional affected 
individuals. Shared variants within the locus between the three affected individuals were prioritized 
based on population frequency (MAF ≤0.0001), and coding, splice site, intronic and intergenic 
heterozygous variants were assessed (Table S4). 
Index family UK1; WES was performed for an affected individual from a genetically unexplained UK 
adRP family (UK1). No rare coding or splice site heterozygous variants (MAF ≤0.0001) were identified 
in IRD-associated genes, so WGS was performed for four affected individuals (Figure 1B). Prioritization 
of rare heterozygous variants in genome data shared by affected individuals in this family failed to 
identify a candidate rare shared heterozygous variant in IRD-associated genes (MAF ≤0.0001); 
however, a disease associated haplotype on chromosome 17 spanning 8 Mb (17q22-17q24.1) was 
identified (Figure 1E). No shared rare (MAF ≤0.0001) coding or splice-site variants were identified 
within the haplotype (Table S5). A deep intronic shared rare (absent from gnomAD) variant 
(g.56293716G>A; c.262-112C>T; NM_001321269.1), in the ciliopathy gene MKS1 (MIM: 609883), was 
initially considered a candidate. This variant was assessed for its potential to alter splicing using 
lymphoblast RNA extracted from affected individuals and controls; however, no difference in pre-
mRNA splicing was observed (data not shown). This rare variant was used as a flag SNV to detect this 
 haplotype in other families. Twelve UK adRP families were found to carry the same founder haplotype 
(Figure 1B and Figure 1C). We then refined the adRP locus, by genotyping SNPs in the extended 
pedigrees, to a 4.4 Mb interval on Chr17q22 (chr17:55,139,138-59,536,883) (Figure 1E). 
 
Identification of structural variants within the RP17-locus  
We analyzed the genome and exome data for CNVs and SVs using Manta, Control-FREEC, Canvas and 
ExomeDepth. In all families, SVs within the RP17-locus were identified. Triplication was suspected from 
read-depth of SNVs observed in IGV for UK-SV6. To validate the presence of a triplicated region, qPCR 
was performed on affected and control genomic DNA for genes and genomic regions implicated in this 
SV, and proximal and distal genomic regions (as additional controls for copy number). 
For all families that harbor SVs in the RP17-locus, reanalysis of sequencing data was performed to 
exclude other potentially pathogenic variants in IRD-associated genes. No pathogenic heterozygous 
coding or splice site variants were observed in genes that have been associated with IRDs (MAF 
≤0.0001). NL2 consists of distantly related affected individuals, who were identified as having a 
common ancestor following the identification of the NL-SV5. In the middle branch of this pedigree, a 
plausible candidate variant in ZNF513 (MIM: 613598) was described previously.35 This variant was 
absent in WGS data of the other two affected individuals of this family, and therefore does not 
segregate with disease and is no longer a candidate variant.  
 
A combination of mutational mechanisms created the RP17-SVs  
Different mutational mechanisms have been described for the formation of complex SVs in the 
genome; including replication-based mechanisms, such as microhomology-mediated break-induced 
replication.36; 37 Therefore, we analyzed all breakpoint junction sequences to investigate the potential 
 mechanism(s) that created RP17-SVs. Analysis of breakpoint sequences in the reference genome using 
the algorithm RepeatMasker identified an enrichment for long repetitive elements (e.g. Alu-elements) 
in all SVs (Table S6). In addition, breakpoint sequences revealed several DNA signatures that are 
indicative of distinct underlying mechanisms. For some SVs (e.g. NL-SV1), microhomology (2-5bp) was 
identified at the breakpoints, whereas longer stretches of homology (>100bp) were identified for 
breakpoints of UK-SV6 and UK-SV7. In these cases, (micro)homology-mediated repair is the likely 
mechanism giving rise to the SV. For other breakpoints (e.g. UK-SV1), small insertions and deletions 
were observed at breakpoint junctions, suggesting non-homologous end joining events (Table S8, 
Figure S4). In all SVs, there is a high content of repetitive elements, suggesting these play a role in both 
repair mechanisms. 
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